UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 133

Sortiert nach

Treatment of glioblastoma in adults

Therapeutic Advances in Neurological Disorders, 2018-01, Vol.11, p.1756286418790452

2018

Volltextzugriff (PDF)

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Nature (London), 2021-04, Vol.592 (7854), p.463-468

2021

Volltextzugriff (PDF)

Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

Clinical cancer research, 2016-12, Vol.22 (23), p.5765-5771

2016

Volltextzugriff (PDF)

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1027-1037

2017

Volltextzugriff (PDF)

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Investigational new drugs, 2020-10, Vol.38 (5), p.1570-1579

2020

Volltextzugriff (PDF)

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Journal of clinical oncology, 2013-09, Vol.31 (26), p.3212-3218

2013

Volltextzugriff (PDF)

PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma

BMC cancer, 2024-01, Vol.24 (1), p.135-135, Article 135

2024

Volltextzugriff (PDF)

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

Neuro-oncology (Charlottesville, Va.), 2015-08, Vol.17 (8), p.1139-1147

2015

Volltextzugriff (PDF)

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Neuro-oncology (Charlottesville, Va.), 2023-02, Vol.25 (2), p.339-350

2023

Volltextzugriff (PDF)

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3357-3361

2007

Volltextzugriff (PDF)

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?

Journal of neuro-oncology, 2021-05, Vol.152 (3), p.483-490

2021

Volltextzugriff (PDF)

Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07)

BMC cancer, 2024-04, Vol.24 (1), p.449-449, Article 449

2024

Volltextzugriff (PDF)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Neurological research and practice, 2022-05, Vol.4 (1), p.20-20, Article 20

2022

Volltextzugriff (PDF)

Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma

Neuro-oncology (Charlottesville, Va.), 2016-12, Vol.18 (12), p.1673-1679

2016

Volltextzugriff (PDF)

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

Current neurology and neuroscience reports, 2011-06, Vol.11 (3), p.305-312

2011

Volltextzugriff (PDF)

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Molecular cancer research, 2018-05, Vol.16 (5), p.767-776

2018

Volltextzugriff (PDF)

Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt

The Journal of neuroscience, 2002-08, Vol.22 (15), p.6401-6407

2002

Volltextzugriff (PDF)

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.CT025-CT025

2021

Volltextzugriff (PDF)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma

Oncotarget, 2015-10, Vol.6 (31), p.31050-31068

2015

Volltextzugriff (PDF)

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes

Cancer medicine (Malden, MA), 2020-11, Vol.9 (22), p.8373-8385

2020

Volltextzugriff (PDF)

1 – 25 von 133

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(123)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Englisch
(128)
Japanisch
(14)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment of glioblastoma in adults

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features

MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma

Prophylactic anticoagulation in patients with glioblastoma or brain metastases and atrial fibrillation: an increased risk for intracranial hemorrhage?

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07)

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study

Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma

Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt

Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)

Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma

Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes

Suchergebnisse filtern